Clinical Trial Update: PARP Inhibition for Triple Negative Breast Cancer (ER-/PR-/HER2-)With BRCA1/2 Mutations [Phase 2]

View source ↗

Summary

Phase 2 trial of PARP inhibition in triple-negative breast cancer with BRCA1/2 mutations completed; results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Triple-negative Breast Cancer

Snippet

Sponsor: Hoosier Cancer Research Network | Conditions: Breast Cancer | Phase 2 | Status: COMPLETED | Results posted: 2024-09-19